Render Target: STATIC
Render Timestamp: 2025-03-16T18:53:05.569Z
Commit: a619ae74f66dae0f27639e88da12bcf600e46428
XML generation date: 2025-03-07 13:11:47.710
Product last modified at: 2025-01-01T09:01:37.692Z
Cell Signaling Technology Logo

Basket Updated

0

Items added

1% for the planet logo
PDP - Template Name: Polyclonal Antibody
PDP - Template ID: *******59c6464

4-1BB/CD137/TNFRSF9 Antibody #85495

Filter:
  • WB
Western Blotting Image 1: 4-1BB/CD137/TNFRSF9 Antibody
Western blot analysis of extracts from primary mouse CD8+ T cells, treated with anti-CD3 and anti-CD28 in the presence of mouse interleukin-2, and CTLL-2 cells using 4-1BB/CD137/TNFRSF9 Antibody.

To Purchase # 85495

Cat. # Size Qty. Price
85495S 100 µl
$306

Supporting Data

REACTIVITY M
SENSITIVITY Endogenous
MW (kDa) 24-28, 40-50
SOURCE Rabbit
Application Key:
  • WB-Western Blotting 
Species Cross-Reactivity Key:
  • M-Mouse 
  • Related Products

Product Information

Product Usage Information

Application Dilution
Western Blotting 1:1000

Storage

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.

Protocol

Specificity / Sensitivity

4-1BB/CD137/TNFRSF9 Antibody recognizes endogenous levels of total 4-1BB/CD137/TNFRSF9 protein.

Species Reactivity:

Mouse

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Glu110 of mouse 4-1BB/CD137/TNFRSF9 protein. Antibodies are purified by protein A and peptide affinity chromatography.

Background

TNFRSF9 is a member of the tumor necrosis factor receptor superfamily (1,2). It is also called 4-1BB or CD137 (1, 2). 4-1BB/CD137/TNFRSF9 is expressed in activated CD4+ and CD8+ T cells, natural killer cells and dendritic cells (2-5). The ligand 4-1BBL/CD137L/TNFSF9 on antigen presenting cells binds to 4-1BB/CD137/TNFRSF9 and costimulates the activation of T cells (5). The binding of agonistic antibodies to 4-1BB/CD137/TNFRSF9 also leads to costimulation for T cell activation (5). Studies have shown the effectiveness of targeting 4-1BB/CD137/TNFRSF9 by its agonistic antibodies in cancer immunotherapy (6).
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
All other trademarks are the property of their respective owners. Visit our Trademark Information page.